Home › Research › Treatments
Amyloid spatial extent with florbetapir-PET for early detection of preclinical Alzheimer’s disease
Emma G. Thibault, Grace A Del Carmen Montenegro, John Alex Becker, Julie C. Price, B.F Healy, Bernard Jimmy Hanseeuw, Rachel F. Buckley, Heidi I.L. Jacobs et al.. The Journal of Prevention of Alzheimer s Disease, 2026-03-13
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
EXT showed high cross-sectional reliability and longitudinal stability. Using EXT reclassified 21.4% of SUVR-participants from Aβ- to Aβ+ and predicted who would progress to SUVR+ 5.5 years later with 83% sensitivity and 94% specificity. In SUVR- individuals, higher pTau217 associated with greater SUVR only within EXT+ individuals. Baseline EXT outperformed SUVR in predicting MTL tau proliferation. For neocortical tau SUVR and PACC change, EXT was the better predictor in earlier Aβ stages (while Aβ spread) while SUVR was superior later (after Aβ was widespread). EXT is a robust, generalizable PET metric that detects Aβ before global positivity and early Aβ-related changes in tau and cognition, supporting its relevance for trial enrichment and early therapeutic monitoring in AD prevention trials.
What this study adds
Evidence grade: Moderate
This is a cross-sectional study. A new amyloid PET measure called EXT detected amyloid before global positivity, reclassified 21.4% of participants from amyloid-negative to amyloid-positive, and predicted progression to amyloid positivity 5.5 years later with 83% sensitivity and 94% specificity. Reported effect size: 21.4%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Thibault, E. G., Montenegro, G. A. D. C., Becker, J. A., Price, J. C., Healy, B., Hanseeuw, B. J., et al. (2026). Amyloid spatial extent with florbetapir-PET for early detection of preclinical Alzheimer’s disease. The Journal of Prevention of Alzheimer s Disease. https://doi.org/10.1016/j.tjpad.2026.100529
Vancouver
Thibault EG, Montenegro GADC, Becker JA, Price JC, Healy B, Hanseeuw BJ, et al. Amyloid spatial extent with florbetapir-PET for early detection of preclinical Alzheimer’s disease. The Journal of Prevention of Alzheimer s Disease. 2026. doi:10.1016/j.tjpad.2026.100529. PMID: 41830758.
BibTeX
@article{thibault2026-41830758,
author = {Thibault, Emma G. and Montenegro, Grace A Del Carmen and Becker, John Alex and Price, Julie C. and Healy, B.F and Hanseeuw, Bernard Jimmy and Buckley, Rachel F. and Jacobs, Heidi I.L. and others},
title = {{Amyloid spatial extent with florbetapir-PET for early detection of preclinical Alzheimer’s disease}},
journal = {The Journal of Prevention of Alzheimer s Disease},
year = {2026},
doi = {10.1016/j.tjpad.2026.100529},
pmid = {41830758},
url = {https://doi.org/10.1016/j.tjpad.2026.100529}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- EXT showed high cross-sectional reliability and longitudinal stability.
- Using EXT reclassified 21.4% of SUVR-participants from Aβ- to Aβ+ and predicted who would progress to SUVR+ 5.5 years later with 83% sensitivity and 94% specificity.
- In SUVR- individuals, higher pTau217 associated with greater SUVR only within EXT+ individuals.
- Baseline EXT outperformed SUVR in predicting MTL tau proliferation.
- For neocortical tau SUVR and PACC change, EXT was the better predictor in earlier Aβ stages (while Aβ spread) while SUVR was superior later (after Aβ was widespread).
Why it matters
A new amyloid PET measure called EXT detected amyloid before global positivity, reclassified 21.4% of participants from amyloid-negative to amyloid-positive, and predicted progression to amyloid positivity 5.5 years later with 83% sensitivity and 94% specificity. The authors say this supports its relevance for trial enrichment and early therapeutic monitoring in Alzheimer's prevention trials.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcross-sectional
- Effect size21.4%
- Evidence strengthModerate
How this study scored 46/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 44 of the 96 points we could judge it on, which is 46 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Journal of Prevention of Alzheimer s Disease) |
| Journal's citation record | 0 / 4 | The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41830758) |
| Free to read | 2 / 2 | Free to read |
| Points | 44 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 44 of the 96 points we could judge it on is 46 out of 100. |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.tjpad.2026.100529
- PubMed: 41830758
- Original source →
- Free full text: The Journal of Prevention of Alzheimer s Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 25.
Related studies in Treatments from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.